Abstract

EXTENDED SPECTRUM BETA LACTAMASES PRODUCING GRAM NEGATIVE BACILLI FROM VARIOUS CLINICAL SAMPLES

Raja Vinodhini*, Chinnasamy Kanimozhi, Periyannan Palanivel, Thambidurai Punitha, Ashokapuram Selvam Saranya and Murugesan Bhuvaneshwari

ABSTRACT

The frequency of Extended Spectrum Beta Lactamases producing strains among clinical isolates has been steadily increasing over the past few years resulting in limitation of the therapeutic options. The present study has been undertaken to detect the presence of ESBLs producing species in various clinical samples. A total of 80 samples were received from VIVA laboratory there were 20 urine samples, 20 pus, 20 stools and 20 throat samples were collected. The study consists of 76 various clinical isolates from various clinical samples such as Staphylococcus aureus 24(31.58%), Escherichia coli 15(19.74%), Klebsiella spp. 23(30.26%), Pseudomonas aeruginosa 7(9.21%), Salmonella spp. 4(5.26%) and Shigella spp. 3(3.95%). The majority of isolates were obtained from pus, stool and throat samples followed by urine. Antimicrobial susceptibility test be performed using Kirby Bauer disc-diffusion method. There were 6 various antibiotics such as Ampicillin, Amoxicillin, Gentamycin, Amikacin, Chloramphenical and Tetracycline were used against clinical isolates. Among the antibiotics tested, all the antibiotics showed the maximum inhibitory activity against particular organisms. Then these 76 clinical isolates were tested for ESBL production by using screening test and double disc synergy test. From the primary screening Staphylococcus aureus (1), Escherichia coli (9), Klebsiella spp. (21), Pseudomonas aeruginosa (6), Salmonella spp. (3) and Shigella spp. (1) showed the positive result for the ESBL production. Among that Escherichia coli 6(40.0%), Klebsiella spp. 19(82.60%), Pseudomonas aeruginosa 2(28.57%) and Salmonella spp. 2(50.0%) were confirmed as ESBL producers by double disc synergy test.

Keywords: Antimicrobial Resistance, Extended Spectrum Beta Lactamases, Screening Test, Double Disc Synergy test.